Literature DB >> 9548821

Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.

B E Maryanoff1, M J Costanzo, S O Nortey, M N Greco, R P Shank, J J Schupsky, M P Ortegon, J L Vaught.   

Abstract

We have explored the structure-activity relationship (SAR) surrounding the clinically efficacious antiepileptic drug topiramate (1), a unique sugar sulfamate anticonvulsant that was discovered in our laboratories. Systematic structural modification of the parent compound was directed to identifying potent anticonvulsants with a long duration of action and a favorable neurotoxicity index. In this context, we have probed the pharmacological importance of several molecular features: (1) the sulfamate group (6-8, 22-25, 27, 84), (2) the linker between the sulfamate group and the pyran ring (9, 10, 21a,b), (3) the substituents on the 2,3- (58-60, 85, 86) and 4, 5-fused (30-38, 43, 45-47, 52, 53) 1,3-dioxolane rings, (4) the constitution of the 4,5-fused 1,3-dioxolane ring (2, 54, 55, 63-68, 76, 77, 80, 83a-r, 84-87, 90a, 91a, 93a), (5) the ring oxygen atoms (95, 96, 100-102, 104, 105), and (6) the absolute stereochemistry (106 and 107). We established the C1 configuration as R for the predominant alcohol diastereomer from the highly selective addition of methylmagnesium bromide to aldehyde 15 (16:1 ratio) by single-crystal X-ray analysis of the major diastereomer of sulfamate 21a. Details for the stereoselective syntheses of the hydrindane carbocyclic analogues 95, 96, 100, and 104 are presented. We also report the synthesis of cyclic imidosulfites 90a and 93a, and imidosulfate 91a, which are rare examples in the class of such five-membered-ring sulfur species. Imidosulfite 93a required the preparation and use of the novel sulfur dichloride reagent, BocN=SCl2. Our SAR investigation led to the impressive 4,5-cyclic sulfate analogue 2 (RWJ-37947), which exhibits potent anticonvulsant activity in the maximal electroshock seizure (MES) test (ca. 8 times greater than 1 in mice at 4 h, ED50 = 6.3 mg/kg; ca. 15 times greater than 1 in rats at 8 h, ED50 = 1.0 mg/kg) with a long duration of action (>24 h in mice and rats, po) and very low neurotoxicity (TD50 value of >1000 mg/kg at 2 h, po in mice). Cyclic sulfate 2, like topiramate and phenytoin, did not interfere with seizures induced by pentylenetetrazole, bicucculine, picrotoxin, and strychnine; also, 2 was not active in diverse in vitro receptor binding and uptake assays. However, 2 turned out to be a potent inhibitor of carbonic anhydrase from different rat tissue sources (e. g., IC50 of 84 nM for the blood enzyme and 21 nM for the brain enzyme). An examination of several analogues of 2 (83a-r, 85-87, 90a, 91a, 93a) indicated that potent anticonvulsant activity is associated with relatively small alkyl substituents on nitrogen (Me/H, 83a; Me/Me, 83m; Et/H, 83b; allyl/H, 83e; c-Pr/H, 83j; c-Bu/H, 83k) and with limited changes in the cyclic sulfate group, such as 4,5-cyclic sulfite 87a/b. The potent anticonvulsants 83a and 83j had greatly diminished carbonic anhydrase inhibitory activity; thus, inhibition of this enzyme may not be a significant factor in the anticonvulsant activity. The alpha-L-sorbopyranoses 67, 68, and 80, which mainly possess a skew conformation (ref 29), were nearly twice as potent as topiramate (1). The L-fructose enantiomers of 1 (106) and 2 (107), synthesized from L-sorbose, were found to have moderate anticonvulsant activity, with eudysmic ratios (MES ED50 in mice at 4 h, po) of 1:106 = 1.5 and 2:107 = 3.5. The log P values for 1 and 2 were determined experimentally to be 0.53 and 0.42, respectively, which are less than the optimal 2.0 for CNS active agents. However, analogues with more favorable calculated log P (clogP) values, in conjunction with just minor steric perturbation according to the developed SAR profile, such as 47 (clogP = 2.09), 83m (1.93), and 86 (1.50), did not display improved potency: 47 is less potent than 1, 83m is equipotent with 2, and 86 is less potent than 2. Although the measured log P value for diethyl analogue 31 is 1.52, this did not translate into enhanced potency relative to 1. (ABSTRACT TRUNCATED)

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548821     DOI: 10.1021/jm970790w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate.

Authors:  Rosario Recacha; Michael J Costanzo; Bruce E Maryanoff; Debasish Chattopadhyay
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

Authors:  David F McComsey; Virginia L Smith-Swintosky; Michael H Parker; Douglas E Brenneman; Ewa Malatynska; H Steve White; Brian D Klein; Karen S Wilcox; Michael E Milewski; Mark Herb; Michael F A Finley; Yi Liu; Mary Lou Lubin; Ning Qin; Allen B Reitz; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2013-11-11       Impact factor: 7.446

3.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

Review 4.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

5.  Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.

Authors:  Aurelija Mickevičiūtė; David D Timm; Marius Gedgaudas; Vaida Linkuvienė; Zhiwei Chen; Abdul Waheed; Vilma Michailovienė; Asta Zubrienė; Alexey Smirnov; Edita Čapkauskaitė; Lina Baranauskienė; Jelena Jachno; Jurgita Revuckienė; Elena Manakova; Saulius Gražulis; Jurgita Matulienė; Enrico Di Cera; William S Sly; Daumantas Matulis
Journal:  Eur Biophys J       Date:  2017-10-03       Impact factor: 1.733

6.  Topiramate hyperpolarizes and modulates the slow poststimulus AHP of rat olfactory cortical neurones in vitro.

Authors:  Emilio Russo; Andrew Constanti
Journal:  Br J Pharmacol       Date:  2003-12-22       Impact factor: 8.739

7.  Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents.

Authors:  Elisabeth Miot-Noirault; Bastien Reux; Eric Debiton; Jean-Claude Madelmont; Jean-Michel Chezal; Pascal Coudert; Valérie Weber
Journal:  Invest New Drugs       Date:  2009-12-23       Impact factor: 3.850

8.  [(3aS,5aR,8aR,8bS)-2,2,7,7-Tetra-methyl-tetra-hydro-3aH-bis-[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl (R)-N-(1-phenyl-eth-yl)sulfamate.

Authors:  Meng Xie; Si-Si Shen; Bao-Feng Chen; Yu Sha
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-28

9.  The effect of topiramate on weight loss in patients with type 2 diabetes.

Authors:  Sedighe Moradi; Scott Reza Jafarian Kerman; Mina Mollabashi
Journal:  J Res Med Sci       Date:  2013-04       Impact factor: 1.852

10.  Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.

Authors:  Clifford M Knapp; Domenic A Ciraulo; Ofra Sarid-Segal; Mark A Richardson; Eric Devine; Chris C Streeter; Marlene Oscar-Berman; Caitlin Surprise; Laurie Colaneri; Meghan Putnam; Megan Waters; Courtney Richambault
Journal:  J Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.